HER-2/neu detection in fine-needle aspirates of breast cancer - Fluorescence in situ hybridization and immunocytochemical analysis

被引:59
作者
Beatty, BG
Bryant, R
Wang, WC
Ashikaga, T
Gibson, PC
Leiman, G
Weaver, DL
机构
[1] Univ Vermont, Coll Med, Dept Pathol, Burlington, VT 05405 USA
[2] Univ Vermont, Coll Med, Dept Biostat, Burlington, VT 05405 USA
[3] Vermont Reg Canc Ctr, Burlington, VT USA
关键词
HER-2/neu; breast cancer; fine-needle aspirate; immunocytochemistry; immunohistochemistry; fluorescence in situ hybridization;
D O I
10.1309/X8UP920UF4XM1C5C
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
We evaluated HER-2 receptor status by immunocytochemical and immunohistochemical analyses and fluorescence in situ hybridization (FISH) in 51 fine-needle aspiration (FNA) specimens together with the corresponding formalin-fixed, paraffin-embedded (FFPE) tissue samples obtained from surgically resected breast cancers. Three fixation methods were compared ethanol, formalin, and CytoLyt-ThinPrep (Cytyc, Boxborough, MA). HER-2 was overexpressed and amplified in 8 (16%) of 51 FFPE specimens. Of the 8 cases, gene amplification was observed in 8 FNA specimens (100%) and overexpression in 2 (25%) ethanol-, 4 (50%) CytoLyt-, and 5 (63%)formalin-fixed FNA specimens. Strong pairwise kappa association between FISH results performed on FNA specimens and FFPE tissue samples (ethanol fixation, kappa = 0.848; ThinPrep, kappa = 0.918) and moderate (ThinPrep, kappa = 0.692; formalin fixation, kappa = 0.667) to poor (ethanol, kappa = 0.300) pairwise kappa agreement between tissue immunohistochemical and FNA immunocytochemical results was demonstrated. We conclude that HER-2 protein expression on cytologic preparations was insufficiently reliable for clinical use, whereas HER-2 gene amplification determined by FISH demonstrated strong and consistent correlation with HER-2 status of FFPE tissue samples.
引用
收藏
页码:246 / 255
页数:10
相关论文
共 46 条
[21]  
Makris A, 1997, CLIN CANCER RES, V3, P593
[22]  
Masood S, 2000, ANN CLIN LAB SCI, V30, P259
[23]  
MASS RD, 2001, P AN M AM SOC CLIN, V20, P85
[24]   Fluorescence in situ hybridisation detection of erbB2 amplification in breast cancer fine needle aspirates [J].
McManus, DT ;
Patterson, AH ;
Maxwell, P ;
Humphreys, MW ;
Anderson, NH .
JOURNAL OF CLINICAL PATHOLOGY-MOLECULAR PATHOLOGY, 1999, 52 (02) :75-77
[25]   c-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates [J].
Mezzelani, A ;
Alasio, L ;
Bartoli, C ;
Bonora, MG ;
Pierotti, MA ;
Rilke, F ;
Pilotti, S .
BRITISH JOURNAL OF CANCER, 1999, 80 (3-4) :519-525
[26]   C-ERBB-2 EXPRESSION AND RESPONSE TO ADJUVANT THERAPY IN WOMEN WITH NODE-POSITIVE EARLY BREAST-CANCER [J].
MUSS, HB ;
THOR, AD ;
BERRY, DA ;
KUTE, T ;
LIU, ET ;
KOERNER, F ;
CIRRINCIONE, CT ;
BUDMAN, DR ;
WOOD, WC ;
BARCOS, M ;
HENDERSON, IC .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (18) :1260-1266
[27]   Immunocytochemical evaluation of HER-2/neu on fine-needle aspirates from primary breast carcinomas [J].
Nizzoli, R ;
Bozzetti, C ;
Crafa, P ;
Naldi, N ;
Guazzi, A ;
Di Blasio, B ;
Camisa, R ;
Cascinu, S .
DIAGNOSTIC CYTOPATHOLOGY, 2003, 28 (03) :142-146
[28]  
PATERSON MC, 1991, CANCER RES, V51, P556
[29]   Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer:: A direct comparison of fluorescence in situ hybridization and immunohistochemistry [J].
Pauletti, G ;
Dandekar, S ;
Rong, HM ;
Ramos, L ;
Pong, HJ ;
Seshadri, R ;
Slamon, DJ .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (21) :3651-3664
[30]  
Pauletti G, 1996, ONCOGENE, V13, P63